| SIRT1 is an in vitro and in vivo deacetylase binding partner for retinoblastoma tumor suppressor protein and its family members p107 and p130. | retinoblastoma, |
| Studies provide novel evidence for a checkpoint function of Sirt1 in the development of PIN and further highlight a role for SIRT1 as a tumor suppressor in the prostate. | prostate, |
| SIRT1 expression induced by ERalpha was sufficient to activate antioxidant & prosurvival genes in breast cancer cells & to inactivate tumor suppressor genes. | breast, |
| SIRT1 expression was gradually decreased during the normal-adenoma-adenocarcinoma-metastasis sequence, suggesting a possible role of SIRT1 in tumour suppression in the colorectum, and a probable link to the microsatellite instability pathway. | colorectal, |
| As the nuclear SIRT1 functions as a tumor promoter and cytoplasmic SIRT1 functions as a tumor suppressor, the role of SIRT1 in HCC should be reconsidered. | liver, |
| support a role of SIRT1 protein as tumor suppressor in luminal A breast cancer | breast, |
| SIRT1 is a potential tumor suppressor in Oral squamous cell carcinoma (OSCC). | oral, |
| this work demonstrates a tumor suppressive role of SIRT1 in the development of K-RAS-driven lung adenocarcinomas in mice and humans. | lung, |
| SIRT1 suppresses intestinal tumor formation in vitro | None |
| Report impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. SIRT1 may act as a tumor suppressor through its role in DNA damage response and genome integrity. | None |
| Results identify a c-Myc-SIRT1 feedback loop in the regulation of c-Myc activity and cellular transformation, supporting/suggesting a role of SIRT1 in tumor suppression. | None |
| Results provide direct proof of the anti-ageing activity of Sirt1 in mammals and of its tumour suppression activity in ageing- and metabolic syndrome-associated cancer. | None |
| Allelic loss or mutations in the SIRT1 gene occur prevalently during tumorigenesis, indicating that SIRT1 may serve as a tumor suppressor. | None |
| The results of the work presented here add to the growing body of evidence that Sirt1 is neither an outright oncogene nor a tumor suppressor. | None |
| Data indicate that transgenic Sirt1 expression is oncogenic in thyroid carcinogenesis initiated by Pten-deficiency, and increases c-MYC transcriptional programs. | thyroid, |
| MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma. | liver, |
| data suggest that SIRT1 is an oncogenic factor in breast cancer cells and can be involved in the progression of breast cancer by inhibiting p53 and activating POLD1 | breast, |
| The seemingly opposite oncogenic and tumour-suppressive effects of SIRT1 depends on the status of p53. | None |
| oncogenic SIRT1 undergoes posttranslational regulation and proteasomal degradation with curcumin through covalent modification of SIRT1 at the cysteine 67 residue | None |
| The results of the work presented here add to the growing body of evidence that Sirt1 is neither an outright oncogene nor a tumor suppressor. | None |